RemeGen Co

RemeGen Co Forward P/E

The Forward P/E Ratio of RemeGen Co (688331.SS) as of Oct 26, 2026 is 71.21. In the previous year, Forward P/E Ratio was -34.36 — a change of -307.24% (higher).

Forward P/E

71.21

YoY

-307.24%

Last updated:

Forward P/E Ratio of RemeGen Co is 2025 71.21 . Forward P/E Ratio of RemeGen Co was 2024 -34.36 . It decreases by -307.24% higher compared to the previous year.

The RemeGen Co Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-186.90 CNY
Jan 1, 2019
-117.26 CNY
Jan 1, 2020
-72.30 CNY
Jan 1, 2021
182.63 CNY
Jan 1, 2022
-50.51 CNY
Jan 1, 2023
-33.39 CNY
Jan 1, 2024
-34.36 CNY
Jan 1, 2025
71.21 CNY
The RemeGen Co Forward P/E history
YEARForward P/EYoY
71.21-307.24%
-34.36+2.92%
-33.39-33.91%
-50.51-127.66%
182.63-352.60%
-72.30-38.34%
-117.26-37.26%
-186.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Forward P/E Ratio of RemeGen Co is 71.21 in 2025.

Forward P/E Ratio of RemeGen Co changed from -34.36 to 71.21, representing a -307.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's RemeGen Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — RemeGen Co

All Key Metrics — RemeGen Co